Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells
New GPNMB CAR-T cell therapy shows potential to treat aggressive glioblastoma by targeting both tumors and their immune cell accomplices.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Researchers are developing an immunotherapy strategy using GPNMB CAR-T cells to combat glioblastoma. This approach utilizes cytokine-armoured therapy to target aggressive brain tumors and the myeloid cells that assist them.
Coverage from Nature, Medical Xpress, and News-Medical emphasizes the potential for this dual-targeting method to eliminate aggressive tumors. The Telegraph describes the target as the deadliest form of brain cancer.
Future developments will focus on the efficacy of this immunotherapy strategy and the performance of the cytokine-armoured CAR T cells in treating these brain tumors.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
What specific cells are being used in this therapy?
The therapy utilizes GPNMB CAR-T cells.
What makes this immunotherapy strategy different?
It employs a dual tumour–myeloid targeting approach, focusing on both the tumors and their immune cell accomplices.
What is the primary target of this treatment?
The treatment targets aggressive glioblastoma, a form of brain cancer.
Coverage (7)
- McMaster-Developed Immunotherapy Strategy Targets Aggressive Brain Tumours and Their Fuel Newswise · 3h ago
- Immunotherapy Strategy Shows Promise for Deadly Brain Cancer Northwestern University · 3h ago
- CAR-T cell therapy shows potential to eliminate aggressive glioblastoma News-Medical · 4h ago
- Cytokine-armoured CAR T therapy shows promise against aggressive glioblastoma Labmate-Online · 4h ago
- New immunotherapy strategy targets aggressive brain tumors and their immune cell accomplices Medical Xpress · 4h ago
- Deadliest brain cancer could be treated with immunotherapy The Telegraph · 4h ago
- Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells Nature · 4h ago
Topics
Related trends
GABA Immune Pathway Drives Female Brain Cancer Growth
Researchers have identified a sex-specific immune pathway that drives aggressive brain cancer growth in females.